Research On Preparation and Evaluation of Diclofenac Sodium Copper Oxide Nanoparticles

This study aimed to formulate and evaluate diclofenac sodium copper oxide (CuO) nanoparticles for improved drug delivery. Diclofenac sodium CuO nanoparticles were synthesized via a chemical precipitation method using copper chloride dihydrate as a cross-linking agent and sodium borohydride as a reducing agent. Three formulations (F1, F2, and F3) with varying diclofenac sodium concentrations (0.25M, 0.37M, and 0.5M, respectively) were prepared and characterized. The nanoparticles were characterized using FTIR spectroscopy to confirm the presence of diclofenac sodium and CuO. Key characterization parameters included drug content, particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. In vitro dissolution studies were conducted to evaluate the drug release behavior. Results indicated that formulation F3 (0.5M diclofenac sodium) exhibited the highest entrapment efficiency, optimal particle size, and a favorable zeta potential compared to F1 and F2. Specifically, F3 demonstrated [Insert specific values for entrapment efficiency, particle size, and zeta potential here, e.g., “An entrapment efficiency of X%, a particle size of Y nm and a zeta potential of Z mV”]. These findings suggest that increasing the diclofenac sodium concentration within the nanoparticle formulation can enhance key properties relevant to drug delivery. F3 shows promise as an intermediate for further dosage form development. Future studies will focus on stability analysis, in vivo evaluation, and incorporation of the nanoparticles into suitable dosage forms.